Kuderer, N. M., Desai, A., Lustberg, M. B. & Lyman, G. H. Mitigating acute chemotherapy-associated adverse events in patients with cancer. Nat. Rev. Clin. Oncol. 19, 681–697 (2022).
National Coalition for Cancer Survivorship. State of Survivorship Survey: 2022 https://canceradvocacy.org/2022-state-of-cancer-survivorship-survey/ (2022).
Vaz-Luis, I. et al. Long-term longitudinal patterns of patient-reported fatigue after breast cancer: a group-based trajectory analysis. J. Clin. Oncol. 40, 2148–2162 (2022).
Bower, J. E. Cancer-related fatigue — mechanisms, risk factors, and treatments. Nat. Rev. Clin. Oncol. 11, 597–609 (2014).
Thong, M. S. Y. et al. Cancer-related fatigue: causes and current treatment options. Curr. Treat. Options Oncol. 21, 17 (2020).
Smeland, K. B. et al. Chronic fatigue is highly prevalent in survivors of autologous stem cell transplantation and associated with IL-6, neuroticism, cardiorespiratory fitness, and obesity. Bone Marrow Transpl. 54, 607–610 (2019).
Reinertsen, K. V. et al. Predictors and course of chronic fatigue in long-term breast cancer survivors. J. Cancer Surviv. 4, 405–414 (2010).
Husson, O. et al. Variation in fatigue among 6011 (long-term) cancer survivors and a normative population: a study from the population-based PROFILES registry. Support. Care Cancer 23, 2165–2174 (2015).
Steen, R. et al. A study of chronic fatigue in Norwegian cervical cancer survivors. Gynecol. Oncol. 146, 630–635 (2017).
Berger, A. M. et al. Cancer-related fatigue, version 2.2015. J. Natl Compr. Canc. Netw. 13, 1012–1039 (2015).
Berger, A. M. & Mooney, K. Dissemination and implementation of guidelines for cancer-related fatigue. J. Natl Compr. Canc. Netw. 14, 1336–1338 (2016).
Bower, J. E. et al. Screening, assessment, and management of fatigue in adult survivors of cancer: an American Society of Clinical Oncology clinical practice guideline adaptation. J. Clin. Oncol. 32, 1840–1850 (2014).
Fabi, A. et al. Cancer-related fatigue: ESMO clinical practice guidelines for diagnosis and treatment. Ann. Oncol. 31, 713–723 (2020).
Jacobsen, P. B. et al. Fatigue in women receiving adjuvant chemotherapy for breast cancer: characteristics, course, and correlates. J. Pain Symptom Manag. 18, 233–242 (1999).
Broeckel, J. A. et al. Characteristics and correlates of fatigue after adjuvant chemotherapy for breast cancer. J. Clin. Oncol. 16, 1689–1696 (1998).
Ryan, J. L. et al. Mechanisms of cancer-related fatigue. Oncologist 12, 22–34 (2007).
Bower, J. E. & Lamkin, D. M. Inflammation and cancer-related fatigue: mechanisms, contributing factors, and treatment implications. Brain Behav. Immun. 30, S48–S57 (2013).
Lee, S. et al. Prediction of breast cancer treatment-induced fatigue by machine learning using genome-wide association data. JNCI Cancer Spectr. 4, pkaa039 (2020).
Charalambous, A. et al. Cancer-related fatigue and sleep deficiency in cancer care continuum: concepts, assessment, clusters, and management. Support. Care Cancer 27, 2747–2753 (2019).
Goedendorp, M. M. et al. Development of fatigue in cancer survivors: a prospective follow-up study from diagnosis into the year after treatment. J. Pain Symptom Manag. 45, 213–222 (2013).
O’Higgins, C. M. et al. The pathophysiology of cancer-related fatigue: current controversies. Support. Care Cancer 26, 3353–3364 (2018).
Eyob, T. et al. Impact of chemotherapy on cancer-related fatigue and cytokines in 1312 patients: a systematic review of quantitative studies. Curr. Opin. Support. Palliat. Care 10, 165–179 (2016).
Dantzer, R. et al. The neuroimmune basis of fatigue. Trends Neurosci. 37, 39–46 (2014).
Inglis, J. E. et al. Nutritional interventions for treating cancer-related fatigue: a qualitative review. Nutr. Cancer 71, 21–40 (2019).
Bower, J. E., Crosswell, A. D. & Slavich, G. M. Childhood adversity and cumulative life stress: risk factors for cancer-related fatigue. Clin. Psychol. Sci. 2, 108–115 (2014).
Bower, J. E. et al. Do all patients with cancer experience fatigue? A longitudinal study of fatigue trajectories in women with breast cancer. Cancer 127, 1334–1344 (2021).
Bower, J. E. et al. Fatigue after breast cancer treatment: biobehavioral predictors of fatigue trajectories. Health Psychol. 37, 1025–1034 (2018).
Di Meglio, A. et al. Development and validation of a predictive model of severe fatigue after breast cancer diagnosis: toward a personalized framework in survivorship care. J. Clin. Oncol. 40, 1111–1123 (2022).
Hammermuller, C. et al. Depression, anxiety, fatigue, and quality of life in a large sample of patients suffering from head and neck cancer in comparison with the general population. BMC Cancer 21, 94 (2021).
Brown, L. F. & Kroenke, K. Cancer-related fatigue and its associations with depression and anxiety: a systematic review. Psychosomatics 50, 440–447 (2009).
Armstrong, T. S. et al. Association of genetic variants with fatigue in patients with malignant glioma. Neurooncol. Pract. 5, 122–128 (2018).
Jean-Pierre, P. et al. Assessment of cancer-related fatigue: implications for clinical diagnosis and treatment. Oncologist 12, 11–21 (2007).
Mendoza, T. R. et al. The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory. Cancer 85, 1186–1196 (1999).
Yellen, S. B. et al. Measuring fatigue and other anemia-related symptoms with the functional assessment of cancer therapy (FACT) measurement system. J. Pain Symptom Manag. 13, 63–74 (1997).
Stein, K. D. et al. Further validation of the multidimensional fatigue symptom inventory-short form. J. Pain Symptom Manag. 27, 14–23 (2004).
Hann, D. M. et al. Measurement of fatigue in cancer patients: development and validation of the fatigue symptom inventory. Qual. Life Res. 7, 301–310 (1998).
Chow, R. et al. Cancer-related fatigue-pharmacological interventions: systematic review and network meta-analysis. BMJ Support. Palliat. Care https://doi.org/10.1136/bmjspcare-2021-003244 (2021).
Popescu, R. A. et al. Supportive care: low cost, high value. Am. Soc. Clin. Oncol. Educ. Book 41, 1–11 (2021).
Lawrence, J. A. et al. A study of donepezil in female breast cancer survivors with self-reported cognitive dysfunction 1 to 5 years following adjuvant chemotherapy. J. Cancer Surviv. 10, 176–184 (2016).
Bruera, E. et al. Donepezil for cancer fatigue: a double-blind, randomized, placebo-controlled trial. J. Clin. Oncol. 25, 3475–3481 (2007).
Paulsen, O. et al. Efficacy of methylprednisolone on pain, fatigue, and appetite loss in patients with advanced cancer using opioids: a randomized, placebo-controlled, double-blind trial. J. Clin. Oncol. 32, 3221–3228 (2014).
Yennurajalingam, S. et al. Reduction of cancer-related fatigue with dexamethasone: a double-blind, randomized, placebo-controlled trial in patients with advanced cancer. J. Clin. Oncol. 31, 3076–3082 (2013).
Yennu, S. V. V. et al. High/low dose dexamethasone with physical activity for cancer-related fatigue in patients with advanced cancer: a phase II randomized double blind study. J. Clin. Oncol. 37 (Suppl. 31), 110 (2019).
Sadeghian, M. et al. Ginseng and cancer-related fatigue: a systematic review of clinical trials. Nutr. Cancer 73, 1270–1281 (2021).
Mustian, K. M. et al. Comparison of pharmaceutical, psychological, and exercise treatments for cancer-related fatigue: a meta-analysis. JAMA Oncol. 3, 961–968 (2017).
Dennett, A. M. et al. Multidisciplinary, exercise-based oncology rehabilitation programs improve patient outcomes but their effects on healthcare service-level outcomes remain uncertain: a systematic review. J. Physiother. 67, 12–26 (2021).
David, A., Hausner, D. & Frenkel, M. Cancer-related fatigue-is there a role for complementary and integrative medicine? Curr. Oncol. Rep. 23, 145 (2021).
Gielissen, M. F. et al. Effects of cognitive behavior therapy in severely fatigued disease-free cancer patients compared with patients waiting for cognitive behavior therapy: a randomized controlled trial. J. Clin. Oncol. 24, 4882–4887 (2006).
Poort, H. et al. Cognitive behavioral therapy or graded exercise therapy compared with usual care for severe fatigue in patients with advanced cancer during treatment: a randomized controlled trial. Ann. Oncol. 31, 115–122 (2020).
Seiler, A. et al. eHealth and mHealth interventions in the treatment of fatigued cancer survivors: a systematic review and meta-analysis. Psychooncology 26, 1239–1253 (2017).
Foster, C. et al. A web-based intervention (RESTORE) to support self-management of cancer-related fatigue following primary cancer treatment: a multi-centre proof of concept randomised controlled trial. Support. Care Cancer 24, 2445–2453 (2016).
Maihofner, C. et al. Chemotherapy-induced peripheral neuropathy (CIPN): current therapies and topical treatment option with high-concentration capsaicin. Support. Care Cancer 29, 4223–4238 (2021).
Salat, K. Chemotherapy-induced peripheral neuropathy: part 1-current state of knowledge and perspectives for pharmacotherapy. Pharmacol. Rep. 72, 486–507 (2020).
Seretny, M. et al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Pain 155, 2461–2470 (2014).
Coradini, P. P. et al. Ototoxicity from cisplatin therapy in childhood cancer. J. Pediatr. Hematol. Oncol. 29, 355–360 (2007).
Landier, W. Ototoxicity and cancer therapy. Cancer 122, 1647–1658 (2016).
Hu, S. et al. Recent developments of novel pharmacologic therapeutics for prevention of chemotherapy-induced peripheral neuropathy. Clin. Cancer Res. 25, 6295–6301 (2019).
Chan, A. et al. Biological predictors of chemotherapy-induced peripheral neuropathy (CIPN): MASCC neurological complications working group overview. Support. Care Cancer 27, 3729–3737 (2019).
St Germain, D. C. et al. Chemotherapy-induced peripheral neuropathy: identifying the research gaps and associated changes to clinical trial design. Cancer 126, 4602–4613 (2020).
Loprinzi, C. L. et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update. J. Clin. Oncol. 38, 3325–3348 (2020).
Jordan, B. et al. Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO-EONS-EANO clinical practice guidelines for diagnosis, prevention, treatment and follow-up. Ann. Oncol. 31, 1306–1319 (2020).
Hertz, D. L. et al. Patient-centric decision framework for treatment alterations in patients with chemotherapy-induced Peripheral Neuropathy (CIPN). Cancer Treat. Rev. 99, 102241 (2021).
Mizrahi, D. et al. Development and consensus process for a clinical pathway for the assessment and management of chemotherapy-induced peripheral neuropathy. Support. Care Cancer 30, 5965–5974 (2022).
Tan, A. C. et al. Chemotherapy-induced peripheral neuropathy-patient-reported outcomes compared with NCI-CTCAE grade. Support. Care Cancer 27, 4771–4777 (2019).
McCrary, J. M. et al. Optimal clinical assessment strategies for chemotherapy-induced peripheral neuropathy (CIPN): a systematic review and Delphi survey. Support. Care Cancer 25, 3485–3493 (2017).
Pfeiffer, P. et al. Calmangafodipir for prevention of oxaliplatin-induced peripheral neuropathy: two placebo-controlled, randomized phase 3 studies (POLAR-A/POLAR-M). JNCI Cancer Spectr. 6, pkac075 (2022).
Smith, E. M. et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA 309, 1359–1367 (2013).
Zirpoli, G. R. et al. Supplement use and chemotherapy-induced peripheral neuropathy in a cooperative group trial (S0221): the DELCaP study. J. Natl Cancer Inst. 109, djx098 (2017).
Hershman, D. L. et al. Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy. J. Clin. Oncol. 31, 2627–2633 (2013).
Ambrosone, C. B. et al. Dietary supplement use during chemotherapy and survival outcomes of patients with breast cancer enrolled in a cooperative group clinical trial (SWOG S0221). J. Clin. Oncol. 38, 804–814 (2020).
Greenlee, H. et al. Randomized sham-controlled pilot trial of weekly electro-acupuncture for the prevention of taxane-induced peripheral neuropathy in women with early stage breast cancer. Breast Cancer Res. Treat. 156, 453–464 (2016).
Lu, W. et al. Acupuncture for chemotherapy-induced peripheral neuropathy in breast cancer survivors: a randomized controlled pilot trial. Oncologist 25, 310–318 (2020).
Tsuyuki, S. et al. Evaluation of the effect of compression therapy using surgical gloves on nanoparticle albumin-bound paclitaxel-induced peripheral neuropathy: a phase II multicenter study by the Kamigata Breast Cancer Study Group. Breast Cancer Res. Treat. 160, 61–67 (2016).
Tsuyuki, S. et al. Effectiveness and safety of surgical glove compression therapy as a prophylactic method against nanoparticle albumin-bound-paclitaxel-induced peripheral neuropathy. Breast 47, 22–27 (2019).
Kanbayashi, Y. et al. Comparison of the efficacy of cryotherapy and compression therapy for preventing nanoparticle albumin-bound paclitaxel-induced peripheral neuropathy: a prospective self-controlled trial. Breast 49, 219–224 (2020).
Kanzawa-Lee, G. A. et al. Exercise effects on chemotherapy-induced peripheral neuropathy: a comprehensive integrative review. Cancer Nurs. 43, E172–E185 (2020).
Kleckner, I. R. et al. Effects of exercise during chemotherapy on chemotherapy-induced peripheral neuropathy: a multicenter, randomized controlled trial. Support. Care Cancer 26, 1019–1028 (2018).
Streckmann, F. et al. Exercise program improves therapy-related side-effects and quality of life in lymphoma patients undergoing therapy. Ann. Oncol. 25, 493–499 (2014).
Streckmann, F. et al. Exercise intervention studies in patients with peripheral neuropathy: a systematic review. Sports Med. 44, 1289–1304 (2014).
Mayo, S. J. et al. Cancer-related cognitive impairment in patients with non-central nervous system malignancies: an overview for oncology providers from the MASCC Neurological Complications Study Group. Support. Care Cancer 29, 2821–2840 (2021).
Janelsins, M. C. et al. Prevalence, mechanisms, and management of cancer-related cognitive impairment. Int. Rev. Psychiatry 26, 102–113 (2014).
Williams, A. M., Zent, C. S. & Janelsins, M. C. What is known and unknown about chemotherapy-related cognitive impairment in patients with haematological malignancies and areas of needed research. Br. J. Haematol. 174, 835–846 (2016).
Lange, M. et al. Cancer-related cognitive impairment: an update on state of the art, detection, and management strategies in cancer survivors. Ann. Oncol. 30, 1925–1940 (2019).
Wefel, J. S. et al. International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol. 12, 703–708 (2011).
Mounier, N. M. et al. Chemotherapy-induced cognitive impairment (CICI): an overview of etiology and pathogenesis. Life Sci. 258, 118071 (2020).
Janelsins, M. C. et al. Longitudinal changes in cognitive function in a nationwide cohort study of patients with lymphoma treated with chemotherapy. J. Natl Cancer Inst. 114, 47–59 (2021).
Magnuson, A. et al. Cognitive function in older adults with cancer: assessment, management, and research opportunities. J. Clin. Oncol. 39, 2138–2149 (2021).
Mayo, S. J. et al. Predictors of the trajectory of cognitive functioning in the first 6 months after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transpl. 55, 918–928 (2020).
Mayo, S. J. et al. Late cognitive outcomes among allogeneic stem cell transplant survivors: follow-up data from a 6-year longitudinal study. Support. Care Cancer 29, 2621–2630 (2021).
Ahles, T. A., Root, J. C. & Ryan, E. L. Cancer- and cancer treatment-associated cognitive change: an update on the state of the science. J. Clin. Oncol. 30, 3675–3686 (2012).
Von Ah, D. et al. Cancer, cognitive impairment, and work-related outcomes: an integrative review. Oncol. Nurs. Forum 43, 602–616 (2016).
Duijts, S. F. et al. Cancer-related cognitive impairment and patients’ ability to work: a current perspective. Curr. Opin. Support. Palliat. Care 11, 19–23 (2017).
Mandelblatt, J. S. et al. Cognitive impairment in older patients with breast cancer before systemic therapy: is there an interaction between cancer and comorbidity? J. Clin. Oncol. 32, 1909–1918 (2014).
Huskisson, E., Maggini, S. & Ruf, M. The influence of micronutrients on cognitive function and performance. J. Int. Med. Res. 35, 1–19 (2007).
Mancuso, A. et al. Correlation between anemia and functional/cognitive capacity in elderly lung cancer patients treated with chemotherapy. Ann. Oncol. 17, 146–150 (2006).
Mandelblatt, J. S. et al. Cancer-related cognitive outcomes among older breast cancer survivors in the thinking and living with cancer study. J. Clin. Oncol. 36, JCO1800140 (2018).
Ahles, T. A. et al. The relationship of APOE genotype to neuropsychological performance in long-term cancer survivors treated with standard dose chemotherapy. Psychooncology 12, 612–619 (2003).
Cheng, H. et al. The COMT (rs165599) gene polymorphism contributes to chemotherapy-induced cognitive impairment in breast cancer patients. Am. J. Transl. Res. 8, 5087–5097 (2016).
Lyon, D. E. et al. Relationship of systemic cytokine concentrations to cognitive function over two years in women with early stage breast cancer. J. Neuroimmunol. 301, 74–82 (2016).
Pomykala, K. L. et al. The association between pro-inflammatory cytokines, regional cerebral metabolism, and cognitive complaints following adjuvant chemotherapy for breast cancer. Brain Imaging Behav. 7, 511–523 (2013).
Yap, N. Y. et al. Associations of plasma brain-derived neurotrophic factor (BDNF) and Val66Met polymorphism (rs6265) with long-term cancer-related cognitive impairment in survivors of breast cancer. Breast Cancer Res. Treat. 183, 683–696 (2020).
Tevaarwerk, A. et al. Survivorship, version 1.2021. J. Natl Compr. Canc Netw. 19, 676–685 (2021).
Giesinger, J. M. et al. Replication and validation of higher order models demonstrated that a summary score for the EORTC QLQ-C30 is robust. J. Clin. Epidemiol. 69, 79–88 (2016).
Henneghan, A. M. et al. Measuring self-reported cancer-related cognitive impairment: recommendations from the Cancer Neuroscience Initiative Working Group. J. Natl Cancer Inst. 113, 1625–1633 (2021).
Fernandes, H. A., Richard, N. M. & Edelstein, K. Cognitive rehabilitation for cancer-related cognitive dysfunction: a systematic review. Support. Care Cancer 27, 3253–3279 (2019).
Vardy, J. L. et al. A randomised controlled trial evaluating two cognitive rehabilitation approaches for cancer survivors with perceived cognitive impairment. J. Cancer Surviv. https://doi.org/10.1007/s11764-022-01261-5 (2022).
Campbell, K. L. et al. The effect of exercise on cancer-related cognitive impairment and applications for physical therapy: systematic review of randomized controlled trials. Phys. Ther. 100, 523–542 (2020).
Farahani, M. A. et al. The effect of mind-body exercise on cognitive function in cancer survivors: a systematic review. Can. Oncol. Nurs. J. 32, 38–48 (2022).
Kohli, S. et al. The effect of modafinil on cognitive function in breast cancer survivors. Cancer 115, 2605–2616 (2009).
Brown, P. D. et al. Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial. Neuro-oncology 15, 1429–1437 (2013).
Dos Santos, M. et al. Cognitive rehabilitation program to improve cognition of cancer patients treated with chemotherapy: a 3-arm randomized trial. Cancer 126, 5328–5336 (2020).
Bray, V. J. et al. Evaluation of a web-based cognitive rehabilitation program in cancer survivors reporting cognitive symptoms after chemotherapy. J. Clin. Oncol. 35, 217–225 (2017).
Desai, A. et al. Takotsubo cardiomyopathy in cancer patients. Cardiooncology 5, 7 (2019).
Alexandre, J. et al. Cardiovascular toxicity related to cancer treatment: a pragmatic approach to the American and European Cardio-Oncology Guidelines. J. Am. Heart Assoc. 9, e018403 (2020).
Herrmann, J. Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia. Nat. Rev. Cardiol. 17, 474–502 (2020).
Belzile-Dugas, E. & Eisenberg, M. J. Radiation-induced cardiovascular disease: review of an underrecognized pathology. J. Am. Heart Assoc. 10, e021686 (2021).
Marinescu, D. C. et al. Integration and application of Clinical Practice Guidelines for the diagnosis of idiopathic pulmonary fibrosis and fibrotic hypersensitivity pneumonitis. Chest 162, 614–629 (2022).
Curigliano, G. et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann. Oncol. 31, 171–190 (2020).
Armenian, S. H. et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J. Clin. Oncol. 35, 893–911 (2017).
Ligibel, J. A., Bohlke, K. & Alfano, C. M. Exercise, diet, and weight management during cancer treatment: ASCO Guideline Summary and Q&A. JCO Oncol. Pract. 18, 695–697 (2022).
Campbell, K. L. et al. Exercise guidelines for cancer survivors: consensus statement from international multidisciplinary roundtable. Med. Sci. Sports Exerc. 51, 2375–2390 (2019).
Zardavas, D. et al. Role of troponins I and T and N-terminal prohormone of brain natriuretic peptide in monitoring cardiac safety of patients with early-stage human epidermal growth factor receptor 2-positive breast cancer receiving trastuzumab: a herceptin adjuvant study cardiac marker substudy. J. Clin. Oncol. 35, 878–884 (2017).
Lenihan, D. J. et al. The utility of point-of-care biomarkers to detect cardiotoxicity during anthracycline chemotherapy: a feasibility study. J. Card. Fail. 22, 433–438 (2016).
Kalay, N. et al. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J. Am. Coll. Cardiol. 48, 2258–2262 (2006).
Heck, S. L. et al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): extended follow-up of a 2×2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Circulation 143, 2431–2440 (2021).
Akpek, M. et al. Protective effects of spironolactone against anthracycline-induced cardiomyopathy. Eur. J. Heart Fail. 17, 81–89 (2015).
Shahid, I. et al. Meta-analysis evaluating the use of statins to attenuate cardiotoxicity in cancer patients receiving anthracyclines and trastuzumab-based chemotherapy. Am. J. Cardiol. 156, 142–145 (2021).
Cardinale, D. et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 114, 2474–2481 (2006).
Livi, L. et al. Cardioprotective strategy for patients with nonmetastatic breast cancer who are receiving an anthracycline-based chemotherapy: a randomized clinical trial. JAMA Oncol. 7, 1544–1549 (2021).
Dhamija, E. et al. Chemotherapy-induced pulmonary complications in cancer: significance of clinicoradiological correlation. Indian J. Radiol. Imaging 30, 20–26 (2020).
Libura, J. et al. Risk of chemotherapy-induced pulmonary fibrosis is associated with polymorphic tumour necrosis factor-a2 gene. Eur. Respir. J. 19, 912–918 (2002).
Maldonado, F., Limper, A. H. & Cass, A. S. Pulmonary Toxicity Associated with Systemic Antineoplastic Therapy: Clinical Presentation, Diagnosis, and Treatment https://www.uptodate.com/contents/pulmonary-toxicity-associated-with-systemic-antineoplastic-therapy-clinical-presentation-diagnosis-and-treatment (2021).
Fujimoto, D. et al. Characteristics and prognostic impact of pneumonitis during systemic anti-cancer therapy in patients with advanced non-small-cell lung cancer. PLoS One 11, e0168465 (2016).
Vahid, B. & Marik, P. E. Pulmonary complications of novel antineoplastic agents for solid tumors. Chest 133, 528–538 (2008).
Limper, A. H. Chemotherapy-induced lung disease. Clin. Chest Med. 25, 53–64 (2004).
Jules-Elysee, K. & White, D. A. Bleomycin-induced pulmonary toxicity. Clin. Chest Med. 11, 1–20 (1990).
Blum, R. H., Carter, S. K. & Agre, K. A clinical review of bleomycin — a new antineoplastic agent. Cancer 31, 903–914 (1973).
Kawai, K. et al. Serum creatinine level during chemotherapy for testicular cancer as a possible predictor of bleomycin-induced pulmonary toxicity. Jpn. J. Clin. Oncol. 28, 546–550 (1998).
O’Sullivan, J. M. et al. Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. Ann. Oncol. 14, 91–96 (2003).
Haugnes, H. S. et al. Pulmonary function in long-term survivors of testicular cancer. J. Clin. Oncol. 27, 2779–2786 (2009).
O’Driscoll, B. R. et al. Active lung fibrosis up to 17 years after chemotherapy with carmustine (BCNU) in childhood. N. Engl. J. Med. 323, 378–382 (1990).
White, D. A. et al. Acute chest pain syndrome during bleomycin infusions. Cancer 59, 1582–1585 (1987).
Uzel, I. et al. Delayed onset bleomycin-induced pneumonitis. Urology 66, 195 (2005).
FDA. Bleomycin Sulfate for Injection, USP Label https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/050443s036lbl.pdf (2010).
Freites-Martinez, A. et al. Using the common terminology criteria for adverse events (CTCAE – Version 5.0) to evaluate the severity of adverse events of anticancer therapies. Actas Dermosifiliogr. 112, 90–92 (2021).
Camus, P. et al. Drug-induced and iatrogenic infiltrative lung disease. Clin. Chest Med. 25, 479–519 (2004).
Raghu, G. et al. Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am. J. Respir. Crit. Care Med. 205, e18–e47 (2022).
Desai, A. et al. Antibody-drug conjugates: a promising novel therapeutic approach in lung cancer. Lung Cancer 163, 96–106 (2022).
Thompson, J. A. et al. Management of immunotherapy-related toxicities, version 1.2019. J. Natl Compr. Canc Netw. 17, 255–289 (2019).
Tarantino, P. et al. Interstitial lung disease induced by anti-ERBB2 antibody-drug conjugates: a review. JAMA Oncol. 7, 1873–1881 (2021).
Flaherty, K. R. et al. Nintedanib in progressive fibrosing interstitial lung diseases. N. Engl. J. Med. 381, 1718–1727 (2019).
King, T. E. Jr. et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N. Engl. J. Med. 370, 2083–2092 (2014).
Bober, S. L. & Varela, V. S. Sexuality in adult cancer survivors: challenges and intervention. J. Clin. Oncol. 30, 3712–3719 (2012).
Melisko, M. E. & Narus, J. B. Sexual function in cancer survivors: updates to the NCCN Guidelines for Survivorship. J. Natl Compr. Canc Netw. 14, 685–689 (2016).
Smith, T., Kingsberg, S. A. & Faubion, S. Sexual dysfunction in female cancer survivors: addressing the problems and the remedies. Maturitas 165, 52–57 (2022).
van Basten, J. P. et al. Sexual dysfunction in nonseminoma testicular cancer patients is related to chemotherapy-induced angiopathy. J. Clin. Oncol. 15, 2442–2448 (1997).
Pallotti, F. et al. Long-term follow up of the erectile function of testicular cancer survivors. Front. Endocrinol. 10, 196 (2019).
Jonker-Pool, G. et al. Sexual functioning after treatment for testicular cancer: comparison of treatment modalities. Cancer 80, 454–464 (1997).
Barkatz, J. et al. Sexual dysfunctions of patients treated with orchidectmoy, chemotherapy and retroperitoneal lymphadenectomy, need for systematic andrological care? [French]. Bull. Cancer 106, 915–922 (2019).
Katz, A., Agrawal, L. S. & Sirohi, B. Sexuality after cancer as an unmet need: addressing disparities, achieving equality. Am. Soc. Clin. Oncol. Educ. Book 42, 1–7 (2022).
Robinson, P. J. et al. Aromatase inhibitors are associated with low sexual desire causing distress and fecal incontinence in women: an observational study. J. Sex. Med. 14, 1566–1574 (2017).
Baumgart, J. et al. Sexual dysfunction in women on adjuvant endocrine therapy after breast cancer. Menopause 20, 162–168 (2013).
Smedsland, S. K. et al. Sexual activity and functioning in long-term breast cancer survivors; exploring associated factors in a nationwide survey. Breast Cancer Res. Treat. 193, 139–149 (2022).
Pizzol, D. et al. Prevalence of erectile dysfunction in male survivors of cancer: a systematic review and meta-analysis of cross-sectional studies. Br. J. Gen. Pract. 71, e372–e380 (2021).
Carter, J. et al. Interventions to address sexual problems in people with cancer: American Society of Clinical Oncology Clinical Practice Guideline Adaptation of Cancer Care Ontario Guideline. J. Clin. Oncol. 36, 492–511 (2018).
Cold, S. et al. Systemic or vaginal hormone therapy after early breast cancer: a Danish observational cohort study. J. Natl Cancer Inst. 114, 1347–1354 (2022).
ACOG Committee Opinion No. 659. The use of vaginal estrogen in women with a history of estrogen-dependent breast cancer. Obstet. Gynecol. 127, e93–e96 (2016).
Chung, E. & Brock, G. Sexual rehabilitation and cancer survivorship: a state of art review of current literature and management strategies in male sexual dysfunction among prostate cancer survivors. J. Sex. Med. 10, 102–111 (2013).
Wittmann, D. et al. Guidelines for sexual health care for prostate cancer patients: recommendations of an International Panel. J. Sex. Med. 19, 1655–1669 (2022).
Lee, S. J. et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J. Clin. Oncol. 24, 2917–2931 (2006).
Paoli, D. et al. Spermatogenesis in Hodgkin’s lymphoma patients: a retrospective study of semen quality before and after different chemotherapy regimens. Hum. Reprod. 31, 263–272 (2016).
Oktay, K., Harvey, B. E. & Loren, A. W. Fertility preservation in patients with cancer: ASCO Clinical Practice Guideline Update Summary. J. Oncol. Pract. 14, 381–385 (2018).
Lambertini, M. et al. Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO Clinical Practice Guidelines. Ann. Oncol. 31, 1664–1678 (2020).
Spears, N. et al. Ovarian damage from chemotherapy and current approaches to its protection. Hum. Reprod. Update 25, 673–693 (2019).
Poorvu, P. D. et al. Cancer treatment-related infertility: a critical review of the evidence. JNCI Cancer Spectr. 3, pkz008 (2019).
van Dorp, W. et al. Genetic variation may modify ovarian reserve in female childhood cancer survivors. Hum. Reprod. 28, 1069–1076 (2013).
Su, H. I. et al. Association of cyclophosphamide drug-metabolizing enzyme polymorphisms and chemotherapy-related ovarian failure in breast cancer survivors. Fertil. Steril. 94, 645–654 (2010).
Reimer, T. et al. SLCO1B1*5 polymorphism (rs4149056) is associated with chemotherapy-induced amenorrhea in premenopausal women with breast cancer: a prospective cohort study. BMC Cancer 16, 337 (2016).
Gracia, C. R. et al. Impact of cancer therapies on ovarian reserve. Fertil. Steril. 97, 134–40.e1 (2012).
Thomas-Teinturier, C. et al. Ovarian reserve after treatment with alkylating agents during childhood. Hum. Reprod. 30, 1437–1446 (2015).
Partridge, A. H. et al. Ovarian reserve in women who remain premenopausal after chemotherapy for early stage breast cancer. Fertil. Steril. 94, 638–644 (2010).
Pilsgaard, F. et al. The use of anti-Müllerian hormone for controlled ovarian stimulation in assisted reproductive technology, fertility assessment and -counseling. Acta Obstet. Gynecol. Scand. 97, 1105–1113 (2018).
Dewailly, D. & Laven, J. AMH as the primary marker for fertility. Eur. J. Endocrinol. 181, D45–D51 (2019).
Moolhuijsen, L. M. E. & Visser, J. A. Anti-Mullerian hormone and ovarian reserve: update on assessing ovarian function. J. Clin. Endocrinol. Metab. 105, 3361–3373 (2020).
Oktay, K. et al. Fertility preservation in patients with cancer: ASCO Clinical Practice Guideline Update. J. Clin. Oncol. 36, 1994–2001 (2018).
ESHRE Guideline Group on Female Fertility Preservation et al. ESHRE guideline: female fertility preservation. Hum. Reprod. Open 2020, hoaa052 (2020).
Carrera, P. M., Kantarjian, H. M. & Blinder, V. S. The financial burden and distress of patients with cancer: understanding and stepping-up action on the financial toxicity of cancer treatment. CA Cancer J. Clin. 68, 153–165 (2018).
von Wolff, M. et al. Timing of ovarian stimulation in patients prior to gonadotoxic therapy: an analysis of 684 stimulations. Eur. J. Obstet. Gynecol. Reprod. Biol. 199, 146–149 (2016).
Lambertini, M. et al. Gonadotropin-releasing hormone agonists during chemotherapy for preservation of ovarian function and fertility in premenopausal patients with early breast cancer: a systematic review and meta-analysis of individual patient-level data. J. Clin. Oncol. 36, 1981–1990 (2018).
Chen, J. et al. Construction and cryopreservation of an artificial ovary in cancer patients as an element of cancer therapy and a promising approach to fertility restoration. Hum. Fertil. 25, 651–661 (2022).
Arecco, L. et al. Safety of fertility preservation techniques before and after anticancer treatments in young women with breast cancer: a systematic review and meta-analysis. Hum. Reprod. 37, 954–968 (2022).
Chian, R. C., Uzelac, P. S. & Nargund, G. In vitro maturation of human immature oocytes for fertility preservation. Fertil. Steril. 99, 1173–1181 (2013).
Wood, M. E. et al. Second malignant neoplasms: assessment and strategies for risk reduction. J. Clin. Oncol. 30, 3734–3745 (2012).
Lyman, G. H. et al. Overall survival and risk of second malignancies with cancer chemotherapy and G-CSF support. Ann. Oncol. 29, 1903–1910 (2018).
Travis, L. B. Therapy-associated solid tumors. Acta Oncol. 41, 323–333 (2002).
Ganz, P. A. & Casillas, J. N. Incorporating the risk for subsequent primary cancers into the care of adult cancer survivors: moving beyond 5-year survival. J. Am. Med. Assoc. 324, 2493–2495 (2020).
Sung, H. et al. Association of first primary cancer with risk of subsequent primary cancer among survivors of adult-onset cancers in the United States. J. Am. Med. Assoc. 324, 2521–2535 (2020).
Areethamsirikul, N. & Reece, D. E. The risk of secondary primary malignancies after therapy for multiple myeloma. Leuk. Lymphoma 56, 3012–3021 (2015).
Castro, G. A., Church, A., Pechet, L. & Snyder, L. M. Leukemia after chemotherapy of Hodgkin’s disease. N. Engl. J. Med. 289, 103–104 (1973).
Preisler, H. D. & Lyman, G. H. Acute myelogenous leukemia subsequent to therapy for a different neoplasm: clinical features and response to therapy. Am. J. Hematol. 3, 209–218 (1977).
Crump, M. et al. Risk of acute leukemia following epirubicin-based adjuvant chemotherapy: a report from the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 21, 3066–3071 (2003).
Smith, R. E. et al. Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the National Surgical Adjuvant Breast and Bowel Project Experience. J. Clin. Oncol. 21, 1195–1204 (2003).
Praga, C. et al. Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide. J. Clin. Oncol. 23, 4179–4191 (2005).
Leone, G. et al. Therapy-related leukemia and myelodysplasia: susceptibility and incidence. Haematologica 92, 1389–1398 (2007).
Le Deley, M. C. et al. Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancer. J. Clin. Oncol. 25, 292–300 (2007).
Patt, D. A. et al. Acute myeloid leukemia after adjuvant breast cancer therapy in older women: understanding risk. J. Clin. Oncol. 25, 3871–3876 (2007).
Josting, A. et al. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin’s disease: a report from the German Hodgkin’s Lymphoma Study Group. J. Clin. Oncol. 21, 3440–3446 (2003).
Morton, L. M. et al. Evolving risk of therapy-related acute myeloid leukemia following cancer chemotherapy among adults in the United States, 1975–2008. Blood 121, 2996–3004 (2013).
Travis, L. B. et al. Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin’s lymphoma. J. Natl Cancer Inst. 87, 524–530 (1995).
Mudie, N. Y. et al. Risk of second malignancy after non-Hodgkin’s lymphoma: a British Cohort Study. J. Clin. Oncol. 24, 1568–1574 (2006).
Travis, L. B. et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin’s disease. J. Natl Cancer Inst. 94, 182–192 (2002).
Travis, L. B. et al. Cancer survivorship–genetic susceptibility and second primary cancers: research strategies and recommendations. J. Natl Cancer Inst. 98, 15–25 (2006).
Relling, M. V. et al. Granulocyte colony-stimulating factor and the risk of secondary myeloid malignancy after etoposide treatment. Blood 101, 3862–3867 (2003).
Hershman, D. et al. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy. J. Natl Cancer Inst. 99, 196–205 (2007).
Lyman, G. H. et al. Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review. J. Clin. Oncol. 28, 2914–2924 (2010).
Smith, S. M. et al. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood 102, 43–52 (2003).
Schaapveld, M. et al. Second cancer risk up to 40 years after treatment for Hodgkin’s lymphoma. N. Engl. J. Med. 373, 2499–2511 (2015).
Perez, D. G., Loprinzi, C. & Ruddy, K. J. Lifestyle factors can lead to multiple cancers over a lifetime-here we go again. JAMA Oncol. 7, 505–506 (2021).
Verma, S. et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N. Engl. J. Med. 367, 1783–1791 (2012).
Bergerot, C. D. & Pal, S. K. Shining a light on the psychological burden of cancer. Nat. Med. 28, 637–638 (2022).
Zabora, J. et al. The prevalence of psychological distress by cancer site. Psychooncology 10, 19–28 (2001).
Institute of Medicine (US) Committee on Psychosocial Services to Cancer Patients/Families in a Community Setting. Cancer Care for the Whole Patient: Meeting Psychosocial Health Needs (National Academies Press, 2008).
Riba, M. B. et al. Distress management, version 3.2019, NCCN Clinical Practice Guidelines in Oncology. J. Natl Compr. Canc Netw. 17, 1229–1249 (2019).
Andersen, B. L. et al. Screening, assessment, and care of anxiety and depressive symptoms in adults with cancer: an American Society of Clinical Oncology guideline adaptation. J. Clin. Oncol. 32, 1605–1619 (2014).
Jacobsen, P. B., Wagner, L. I. & New, A. Quality standard: the integration of psychosocial care into routine cancer care. J. Clin. Oncol. 30, 1154–1159 (2012).
Lebel, S. et al. From normal response to clinical problem: definition and clinical features of fear of cancer recurrence. Support. Care Cancer 24, 3265–3268 (2016).
Bergerot, C. D. et al. Fear of cancer recurrence or progression: what is it and what can we do about it? Am. Soc. Clin. Oncol. Educ. Book 42, 1–10 (2022).
Chang, W. H. & Lai, A. G. Cumulative burden of psychiatric disorders and self-harm across 26 adult cancers. Nat. Med. 28, 860–870 (2022).
Heinrich, M. et al. Suicide risk and mortality among patients with cancer. Nat. Med. 28, 852 (2022).
Li, M., Fitzgerald, P. & Rodin, G. Evidence-based treatment of depression in patients with cancer. J. Clin. Oncol. 30, 1187–1196 (2012).
Traeger, L. et al. Evidence-based treatment of anxiety in patients with cancer. J. Clin. Oncol. 30, 1197–1205 (2012).
Bower, J. E. et al. Targeting depressive symptoms in younger breast cancer survivors: the pathways to wellness randomized controlled trial of mindfulness meditation and survivorship education. J. Clin. Oncol. 39, 3473–3484 (2021).
McAlpine, H. et al. A systematic review of types and efficacy of online interventions for cancer patients. Patient Educ. Couns. 98, 283–295 (2015).
Dossett, L. A. et al. The primary care provider (PCP)-cancer specialist relationship: a systematic review and mixed-methods meta-synthesis. CA Cancer J. Clin. 67, 156–169 (2017).
Snyder, C. F. et al. Comorbid condition care quality in cancer survivors: role of primary care and specialty providers and care coordination. J. Cancer Surviv. 9, 641–649 (2015).
Barone, B. B. et al. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA 300, 2754–2764 (2008).
Griffiths, R. I., Keating, N. L. & Bankhead, C. R. Quality of diabetes care in cancer: a systematic review. Int. J. Qual. Health Care 31, 75–88 (2019).
Halpern, M. T. et al. Models of cancer survivorship care: overview and summary of current evidence. J. Oncol. Pract. 11, e19–e27 (2015).
Chan, R. J. et al. Outcomes of cancer survivorship education and training for primary care providers: a systematic review. J. Cancer Surviv. 16, 279–302 (2022).
Earle, C. C. et al. Quality of non-breast cancer health maintenance among elderly breast cancer survivors. J. Clin. Oncol. 21, 1447–1451 (2003).
Khan, N. F., Carpenter, L., Watson, E. & Rose, P. W. Cancer screening and preventative care among long-term cancer survivors in the United Kingdom. Br. J. Cancer 102, 1085–1090 (2010).
Nekhlyudov, L., O’Malley, D. M. & Hudson, S. V. Integrating primary care providers in the care of cancer survivors: gaps in evidence and future opportunities. Lancet Oncol. 18, e30–e38 (2017).
Bober, S. L. et al. Caring for cancer survivors: a survey of primary care physicians. Cancer 115, 4409–4418 (2009).
Cheung, W. Y., Neville, B. A., Cameron, D. B., Cook, E. F. & Earle, C. C. Comparisons of patient and physician expectations for cancer survivorship care. J. Clin. Oncol. 27, 2489–2495 (2009).
Alfano, C. M. et al. Building personalized cancer follow-up care pathways in the United States: lessons learned from implementation in England, Northern Ireland, and Australia. Am. Soc. Clin. Oncol. Educ. Book. 39, 625–639 (2019).
Jones, J. M. et al. Readdressing the needs of cancer survivors during COVID-19: a path forward. J. Natl Cancer Inst. 113, 955–961 (2021).
Qian, A. S. et al. Disparities in telemedicine during COVID-19. Cancer Med. 11, 1192–1201 (2022).
Nekhlyudov, L. et al. Developing a quality of cancer survivorship care framework: implications for clinical care, research, and policy. J. Natl Cancer Inst. 111, 1120–1130 (2019).
Chan, R. J. et al. Effectiveness and implementation of models of cancer survivorship care: an overview of systematic reviews. J. Cancer Surviv. 17, 197–221 (2021).
McBride, C. M., Emmons, K. M. & Lipkus, I. M. Understanding the potential of teachable moments: the case of smoking cessation. Health Educ. Res. 18, 156–170 (2003).
Demark-Wahnefried, W. et al. Riding the crest of the teachable moment: promoting long-term health after the diagnosis of cancer. J. Clin. Oncol. 23, 5814–5830 (2005).
Brown, J. C. et al. Efficacy of exercise interventions in modulating cancer-related fatigue among adult cancer survivors: a meta-analysis. Cancer Epidemiol. Biomark. Prev. 20, 123–133 (2011).
Sweegers, M. G. et al. Which exercise prescriptions improve quality of life and physical function in patients with cancer during and following treatment? A systematic review and meta-analysis of randomised controlled trials. Br. J. Sports Med. 52, 505–513 (2018).
Buffart, L. M. et al. Effects and moderators of exercise on quality of life and physical function in patients with cancer: an individual patient data meta-analysis of 34 RCTs. Cancer Treat. Rev. 52, 91–104 (2017).
Brown, J. C. et al. The efficacy of exercise in reducing depressive symptoms among cancer survivors: a meta-analysis. PLoS One 7, e30955 (2012).
Dalla Via, J., Daly, R. M. & Fraser, S. F. The effect of exercise on bone mineral density in adult cancer survivors: a systematic review and meta-analysis. Osteoporos. Int. 29, 287–303 (2018).
Mercier, J., Savard, J. & Bernard, P. Exercise interventions to improve sleep in cancer patients: a systematic review and meta-analysis. Sleep Med. Rev. 36, 43–56 (2017).
Mitchell, S. A. & Chambers, D. A. Leveraging implementation science to improve cancer care delivery and patient outcomes. J. Oncol. Pract. 13, 523–529 (2017).
Ramsey, S. D., Lyman, G. H. & Bangs, R. Addressing skyrocketing cancer drug prices comes with tradeoffs: pick your poison. JAMA Oncol. 2, 425–426 (2016).
Desai, A. P. et al. Economic cost and sustainability of oral therapies in precision oncology. JCO Oncol. Pract. 18, e1247–e1254 (2022).
Time. How Healthcare Costs Hurt American Workers and Benefit the Wealthy https://time.com/5785945/health-care-problems-america/ (20 February 2020).
Lyman, G. H. Counting the costs of cancer care. Lancet Oncol. 14, 1142–1143 (2013).
Lyman, G. H. & Kuderer, N. Financial toxicity, financial abuse, or financial torture: let’s call it what it is! Cancer Invest. 38, 139–142 (2020).
Knight, T. G. et al. Financial toxicity in adults with cancer: adverse outcomes and noncompliance. J. Oncol. Pract. https://doi.org/10.1200/JOP.18.00120 (2018).
National Cancer Institute. Financial Toxicity. NCI Dictionary of Cancer Terms. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/financial-toxicity (2023).
Huang, I. C. et al. Determinants and consequences of financial hardship among adult survivors of childhood cancer: a report from the St. Jude lifetime cohort study. J. Natl Cancer Inst. 111, 189–200 (2019).
de Souza, J. A. et al. Measuring financial toxicity as a clinically relevant patient-reported outcome: the validation of the COmprehensive Score for financial Toxicity (COST). Cancer 123, 476–484 (2017).
Gilligan, A. M. et al. Death or Debt? National estimates of financial toxicity in persons with newly-diagnosed cancer. Am. J. Med. 131, 1187–1199.e5 (2018).
Lyman, G. H., Zon, R. & Harvey, R. D. Rationale, opportunities, and reality of biosimilar medications. N. Engl. J. Med. 379, 694–695 (2018).
Lyman, G. H. & Henk, H. J. Association of generic imatinib availability and pricing with trends in tyrosine kinase inhibitor use in patients with chronic myelogenous leukemia. JAMA Oncol. 6, 1969–1971 (2020).
Rodriguez, G. et al. ASCO policy statement on biosimilar and interchangeable products in oncology. JCO Oncol. Pract. https://doi.org/10.1200/OP.22.00783 (2023).
Schnipper, L. E. et al. Updating the American Society of Clinical Oncology value framework: revisions and reflections in response to comments received. J. Clin. Oncol. 34, 2925–2934 (2016).
Cherny, N. I. et al. ESMO-magnitude of clinical benefit scale version 1.1. Ann. Oncol. 28, 2340–2366 (2017).
Cherny, N. I. et al. Comparative assessment of clinical benefit using the ESMO-magnitude of clinical benefit scale version 1.1 and the ASCO value framework net health benefit score. J. Clin. Oncol. 37, 336–349 (2019).
Schnipper, L. E. et al. American society of clinical oncology statement: a conceptual framework to assess the value of cancer treatment options. J. Clin. Oncol. 33, 2563–2577 (2015).
Tefferi, A. et al. In support of a patient-driven initiative and petition to lower the high price of cancer drugs. Mayo Clin. Proc. 90, 996–1000 (2015).
Altice, C. K. et al. Financial hardships experienced by cancer survivors: a systematic review. J. Natl Cancer Inst. 109, djw205 (2017).
Desai, A. & Gyawali, B. Financial toxicity of cancer treatment: moving the discussion from acknowledgement of the problem to identifying solutions. EClinicalMedicine 20, 100269 (2020).
Witte, J. et al. Methods for measuring financial toxicity after cancer diagnosis and treatment: a systematic review and its implications. Ann. Oncol. 30, 1061–1070 (2019).
United Nations. Universal Declaration of Human Rights https://www.un.org/en/about-us/universal-declaration-of-human-rights (1948).
National Academies of Sciences, Engineering, and Medicine. Integrating Social Care into the Delivery of Health Care: Moving Upstream to Improve the Nation’s Health (National Academies Press, 2019).
Moullin, J. C. et al. A systematic review of implementation frameworks of innovations in healthcare and resulting generic implementation framework. Health Res. Policy Syst. 13, 16 (2015).
Colquhoun, H. et al. Towards a common terminology: a simplified framework of interventions to promote and integrate evidence into health practices, systems, and policies. Implement. Sci. 9, 51 (2014).